Carcinogenesis · 2006 · 97 citations · 34 references
Life SciencesImmunologyOncologyApoptosisImmunogeneticsMolecular OncologyApoptosis In CancerApoptosis RegulationApoptotic SignalingBreast Cancer Risk AssessmentDeath ReceptorsT Cell Responses To TumorsActivation-induced Cell DeathApoptosis Pathway GeneticsCd8+ Tumor-infiltrating LymphocytesCell ActivationFas LigandFas Ligand-mediated ApoptosisFas-associated Death Domain ProteinLymphocyte Apoptosis
The FAS-FASL system plays crucial role in counterattack of cancer cell against immune system. This study examined the effects of FAS (-1377G/A and -670A/G) and FASL (-844T/C and 7896G/C) polymorphisms on breast cancer risk and apoptosis of T lymphocytes. The effect on breast cancer risk was determined by case-control analysis of 840 patients and 840 controls. The effects on T-lymphocyte apoptosis were determined by activation-induced cell death (AICD) of T cells ex vivo and by analyzing apoptotic tumor-infiltrating lymphocytes (TILs) in breast cancer tissue. We found moderately increased risk associated with FAS -1377AG [odds ratio (OR), 1.29; 95% confidence interval (CI), 1.05-1.59] and -1377AA (OR, 1.36; 95% CI, 1.01-1.82) genotypes compared with the -1377GG genotype and decreased risk associated with FASL -844CT (OR, 0.76; 95% CI, 0.62-0.94) and -844TT (OR, 0.66; 95% CI, 0.43-1.00) genotypes compared with the -844CC genotype. T lymphocytes with the FASL -844CC genotype had heightened FASL expression that is associated with increased AICD of the T cells stimulated by MCF-7 cells or phytohemagglutinin compared with the FASL -844TT genotype (10.38 +/- 4.09% and 24.29 +/- 1.50% versus 6.03 +/- 0.41% and 17.96 +/- 3.66%; P < 0.05 and 0.001). Breast cancer patients with the FASL -844CC genotype had higher apoptotic TILs in their cancer tissues than those with the FASL -844TT genotype (33.7 +/- 1.2% versus 19.1 +/- 2.0%; P = 0.007). These findings indicate that functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer.
34
Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text
Global Cancer Statistics, 2002
Donald Maxwell Parkin, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2005 · 18.4K citations · Full text
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene <i>BRCA1</i>
Yoshio Miki, Jeffrey Swensen, Donna Shattuck-Eidens et al. · Science · 1994 · 6.1K citations
Identification of the breast cancer susceptibility gene BRCA2
Richard Wooster, Graham R. Bignell, Jonathan Lancaster et al. · Nature · 1995 · 3.7K citations